RetinalGenix Technologies Inc. (RTGN) intrinsic value & 10-year financials
RetinalGenix Technologies Inc. (RTGN) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.99
- Market cap
- $74.1M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 1549.9%
- Free cash flow (FY2025)
- —
RTGN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$2.4M | -$0.13 | — | — | 128.6% |
| FY2024 | — | -$4.3M | -$0.24 | — | — | 295.5% |
| FY2023 | — | -$2.1M | -$0.12 | — | — | 169.0% |
| FY2022 | — | -$3.9M | -$0.25 | — | — | 510.4% |
| FY2021 | — | -$2.2M | — | — | — | 799.7% |
| FY2020 | — | -$2.1M | — | — | — | 7396.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
RetinalGenix Technologies Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
RetinalGenix Technologies Inc. has earned high returns on invested capital, averaging 36.7% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
RetinalGenix Technologies Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
RetinalGenix Technologies Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.